ERBB2 and cancer: In post-menopausal women, former smokers who had stopped smoking ≥10 years before cancer diagnosis showed the strongest risk reductions, particularly for HER2+ tumors: (RRR=0.28; 95% CI: 0.11–0.68; p heterogeneity across subtypes = 0.040).